Cargando…
Carfilzomib induced cardiotoxicity in a multiple myeloma patient
Proteasome inhibitors such as carfilzomib are indicated in multiple myeloma patients showing relapse and/or refractoriness of clonal activity. However, this therapy has been associated with a significant incidence of cardiotoxicity, especially in patients with known cardiovascular risk factors. Here...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487899/ https://www.ncbi.nlm.nih.gov/pubmed/32944287 http://dx.doi.org/10.1186/s40959-020-00074-8 |